Annual Report

Report overview

The report describes the company's completed transformation into a patient-centric biopharmaceutical company in 2012, supported by growth in its core medicines and continued investment in its pipeline. It reports a worldwide workforce of 9 048 people across 70 nationalities. The CSR section sets out patient- and planet-centric initiatives, including energy, water, waste and workforce indicators. KPMG provided limited assurance over selected 2012 economic, environmental and social indicators.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2012
Period: 1 January 2012 – 31 December 2012
Publication date: 26 February 2013
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Energy consumption
Water consumption
Waste
Employees
Women on the board
Women in management
Workplace fatalities

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services